Where is Telix Innovations headquartered?

Telix Innovations is recorded with headquarters in Herstal, BE in NovaPharmaNews public regulatory and sponsor datasets.

Is Telix Innovations publicly traded?

Yes — Telix Innovations is listed as a public company with ticker TLX on NYSE in SEC EDGAR-derived records.

What drugs are associated with Telix Innovations?

We link 2 drug profile(s) where Telix Innovations appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Telix Innovations sponsoring?

Telix Innovations is linked to 27 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Telix Innovations as applicant?

3 USPTO PatentsView record(s) name Telix Innovations or a normalized variant as applicant.

What pipeline phases does Telix Innovations have in our database?

Phase distribution from linked programs: phase 1: 11, phase 2: 8, phase 3: 8.

How many US-approved drugs are linked to Telix Innovations?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Telix Innovations hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Telix Innovations?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Telix Innovations data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Telix Innovations Pharmaceuticals Company Profile

Name: Telix Innovations intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: Rue de Hermée 255, Herstal, Région wallonne 4040, BE
Founded: 2015
Employees: 14
Programs: 27
Drugs: 11
Patents: 3

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Telix Innovations is a pharma organization headquartered in Herstal, BE. It trades on NYSE under ticker TLX. Primary therapeutic focus areas include Metastatic Prostate Cancer, Prostate Cancer, Clear Cell Renal Cell Carcinoma, Neoplastic Disease, Metastatic Castration-resistant Prostate Cancer. NovaPharmaNews links 27 clinical program(s), 2 drug profile(s), and 3 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (11), phase 2 (8), phase 3 (8).

Company snapshot

Telix Innovations is a pharmaceutical company developing innovative radiopharmaceutical solutions and a global service provider in the nuclear medicine field, located in Liège, Belgium. Telix Innovations has developed innovative solutions to facilitate the scalable synthesis of “theranostic” radiopharmaceuticals and to ease their daily production in hospitals and radiopharmacies. Telix Innovation'

2 approved product(s) across US/EU regulatory metadata.
27 active pipeline program(s) linked via ClinicalTrials.gov.
3 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Telix Innovations. Not investment advice.

Top assets

View drugs (11) View projects (27)

Lead pipeline drugs

besilesomab
Marketed / approved
eb-psma
Marketed / approved
fluciclovine (18f)
Marketed / approved
fluciclovine f-18
approved

Active clinical programs

177Lu-TLX250 ccRCC
Phase 3
177Lu-TLX591 Metastatic Castration-resistant Prostate Cancer
Phase 3
68Ga-PSMA-11 PCA
Phase 3
89Zr-Girentuximab Clear Cell Renal Cell Carcinoma
Phase 3

Momentum

Proprietary activity score for Telix Innovations.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 28 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Alaunos Therapeutics

TA overlap score 36.8
Peer + 0 momentum

Bristol Myers Squibb

TA overlap score 28
Peer + 0 momentum

NORTHWEST BIOTHERAPEUTICS

TA overlap score 26.6
Peer + 0 momentum

Peking University Biologics

TA overlap score 23

Recent activity

Latest pipeline, patent, and corporate events for Telix Innovations.

Jun 8, 2026 Clinical update
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC — Phase 2
Jun 8, 2026 Clinical update
Zirconium Zr 89 Girentuximab — Phase 2
Jun 8, 2026 Clinical update
Ga-68-PSMA-11 — Phase 3
Jun 8, 2026 Clinical update
Fluciclovine F18 — Phase 2
Jun 8, 2026 Clinical update
68Ga-PSMA-11 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Telix Innovations?

Telix Innovations is a pharma organization headquartered in Herstal, BE. It trades on NYSE under ticker TLX. Primary therapeutic focus areas include Metastatic Prostate Cancer, Prostate Cancer, Clear Cell Renal Cell Carcinoma, Neoplastic Disease, Metastatic Castration-resistant P
Is Telix Innovations publicly traded?

Yes. Telix Innovations is listed with ticker TLX on NYSE per SEC EDGAR records linked on this profile.
What drugs does Telix Innovations develop or market?

We link 11 drug profile(s) where Telix Innovations is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/telix-pharmaceuticals-ltd#company-drugs.
What are the latest developments for Telix Innovations?

In the last 12 months our linked public records show 27 trial program update(s) and 2 US patent grant(s) tied to this profile.
What therapeutic areas does Telix Innovations focus on?

Telix Innovations focuses on Metastatic Prostate Cancer, Prostate Cancer, Clear Cell Renal Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology